AURINIA PHARMACEUTICALS TO PURCHASE KEZAR LIFE SCIENCES FOR $6.955 PER SHARE IN CASH, ALONG WITH A CONTINGENT VALUE RIGHT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy AUPH?
Source: moomoo
Acquisition Announcement: AURINIA Pharmaceuticals has announced its acquisition of KEZAR Life Sciences.
Financial Details: The acquisition is valued at $6.955 per share in cash, along with a contingent value right.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AUPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AUPH
Wall Street analysts forecast AUPH stock price to rise
6 Analyst Rating
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 16.050
Low
13.00
Averages
16.50
High
21.00
Current: 16.050
Low
13.00
Averages
16.50
High
21.00
About AUPH
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Aurinia Acquires Kezar Life Sciences for $6.955 per Share
- Acquisition Details: Aurinia Pharmaceuticals is acquiring Kezar Life Sciences for $6.955 in cash per share, along with a contingent value right, aiming to enhance its product line and market competitiveness through the integration of Kezar's assets.
- Clinical Development Potential: Kezar's zetomipzomib, a potential first-in-class immunoproteasome inhibitor currently in phase 2 trials, has shown durable steroid-sparing remissions, which could provide Aurinia with new treatment options in the autoimmune hepatitis space.
- Financial Benefit Expectations: The transaction also includes potential proceeds from Kezar's collaboration with Everest Medicines and its sale of projects to Enodia Therapeutics, which is expected to generate additional cash flow for Aurinia, further supporting its R&D and market expansion.
- Strategic Development Direction: Aurinia targets LUPKYNIS sales of $305M to $315M for 2026, and the acquisition of Kezar will aid its long-term strategic positioning in the autoimmune disease sector, enhancing its market share.
See More
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences in $6.955 Per Share Deal
- Merger Agreement: Aurinia Pharmaceuticals has entered into a definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash, along with a non-transferable contingent value right (CVR), which is expected to enhance Aurinia's market position in autoimmune disease treatments.
- Positive Stock Reaction: Following the announcement, Kezar's stock surged by 19.02% to $7.33, indicating strong market confidence in the transaction and reflecting investor optimism regarding Aurinia's future growth prospects.
- Transaction Details: Aurinia plans to commence a tender offer by April 13, 2026, to acquire all outstanding shares of Kezar, with the transaction expected to close in the second quarter of 2026, ensuring that all remaining shares not tendered will receive the same cash and CVR consideration.
- Product Development Outlook: Kezar's lead candidate, Zetomipzomib, has shown clinically meaningful results in treating autoimmune hepatitis and has had positive interactions with the FDA, which may accelerate its development; Aurinia's successful track record in this area positions it well to advance this novel therapeutic agent.
See More
AURINIA PHARMACEUTICALS TO PURCHASE KEZAR LIFE SCIENCES FOR $6.955 PER SHARE IN CASH, ALONG WITH A CONTINGENT VALUE RIGHT
Acquisition Announcement: AURINIA Pharmaceuticals has announced its acquisition of KEZAR Life Sciences.
Financial Details: The acquisition is valued at $6.955 per share in cash, along with a contingent value right.
See More
Aurinia Appoints New CEO and CFO Amid Shareholder Concerns
- Management Overhaul: Aurinia Pharmaceuticals has appointed Kevin Tang as the new CEO, replacing Peter Greenleaf, who served for seven years, a move seen by major shareholder MKT Capital as a complete validation of concerns raised over the past three years, indicating a significant shift in corporate governance.
- Financial Leadership Change: Michael Hearne has been appointed as Chief Financial Officer, succeeding Joe Miller, marking a strategic restructuring in financial management aimed at enhancing financial transparency and shareholder trust.
- Clinical Research Initiative: Aurinia plans to initiate a clinical study of Aritinercept for an autoimmune disease in the first half of 2026, showcasing the company's ongoing commitment to R&D and potentially laying the groundwork for future revenue growth.
- Shift in Investor Sentiment: Following the management changes, retail investor sentiment flipped from bearish to bullish, reflecting market optimism towards the new leadership team, with AUPH stock rising over 6% after the announcement.
See More
Aurinia Appoints New CEO to Enhance Shareholder Value
- Leadership Change: Aurinia has appointed Kevin Tang as the new CEO, replacing Peter Greenleaf, a move seen as a positive response to long-standing shareholder demands and a significant shift in corporate governance.
- Compensation Structure Reform: New CEO Tang's decision to accept zero compensation starkly contrasts with former CEO Greenleaf's approximately $26 million payout from 2019 to 2022, which is expected to enhance shareholder confidence and improve financial discipline within the company.
- Cost-Saving Measures: The new management has reduced the board size from nine to six members and discontinued non-core R&D programs generating over $50 million annually, which is anticipated to save substantial costs and further enhance capital allocation efficiency.
- Share Repurchase Program Launch: Aurinia has initiated a $150 million stock repurchase program aimed at increasing earnings per share by reducing the number of shares outstanding, reflecting the company's commitment to shareholder value creation.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
Aurinia Acquires Kezar Life Sciences for $6.955 per Share
- Acquisition Details: Aurinia Pharmaceuticals is acquiring Kezar Life Sciences for $6.955 in cash per share, along with a contingent value right, aiming to enhance its product line and market competitiveness through the integration of Kezar's assets.
- Clinical Development Potential: Kezar's zetomipzomib, a potential first-in-class immunoproteasome inhibitor currently in phase 2 trials, has shown durable steroid-sparing remissions, which could provide Aurinia with new treatment options in the autoimmune hepatitis space.
- Financial Benefit Expectations: The transaction also includes potential proceeds from Kezar's collaboration with Everest Medicines and its sale of projects to Enodia Therapeutics, which is expected to generate additional cash flow for Aurinia, further supporting its R&D and market expansion.
- Strategic Development Direction: Aurinia targets LUPKYNIS sales of $305M to $315M for 2026, and the acquisition of Kezar will aid its long-term strategic positioning in the autoimmune disease sector, enhancing its market share.
See More
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences in $6.955 Per Share Deal
- Merger Agreement: Aurinia Pharmaceuticals has entered into a definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash, along with a non-transferable contingent value right (CVR), which is expected to enhance Aurinia's market position in autoimmune disease treatments.
- Positive Stock Reaction: Following the announcement, Kezar's stock surged by 19.02% to $7.33, indicating strong market confidence in the transaction and reflecting investor optimism regarding Aurinia's future growth prospects.
- Transaction Details: Aurinia plans to commence a tender offer by April 13, 2026, to acquire all outstanding shares of Kezar, with the transaction expected to close in the second quarter of 2026, ensuring that all remaining shares not tendered will receive the same cash and CVR consideration.
- Product Development Outlook: Kezar's lead candidate, Zetomipzomib, has shown clinically meaningful results in treating autoimmune hepatitis and has had positive interactions with the FDA, which may accelerate its development; Aurinia's successful track record in this area positions it well to advance this novel therapeutic agent.
See More
AURINIA PHARMACEUTICALS TO PURCHASE KEZAR LIFE SCIENCES FOR $6.955 PER SHARE IN CASH, ALONG WITH A CONTINGENT VALUE RIGHT
Acquisition Announcement: AURINIA Pharmaceuticals has announced its acquisition of KEZAR Life Sciences.
Financial Details: The acquisition is valued at $6.955 per share in cash, along with a contingent value right.
See More
Aurinia Appoints New CEO and CFO Amid Shareholder Concerns
- Management Overhaul: Aurinia Pharmaceuticals has appointed Kevin Tang as the new CEO, replacing Peter Greenleaf, who served for seven years, a move seen by major shareholder MKT Capital as a complete validation of concerns raised over the past three years, indicating a significant shift in corporate governance.
- Financial Leadership Change: Michael Hearne has been appointed as Chief Financial Officer, succeeding Joe Miller, marking a strategic restructuring in financial management aimed at enhancing financial transparency and shareholder trust.
- Clinical Research Initiative: Aurinia plans to initiate a clinical study of Aritinercept for an autoimmune disease in the first half of 2026, showcasing the company's ongoing commitment to R&D and potentially laying the groundwork for future revenue growth.
- Shift in Investor Sentiment: Following the management changes, retail investor sentiment flipped from bearish to bullish, reflecting market optimism towards the new leadership team, with AUPH stock rising over 6% after the announcement.
See More
Aurinia Appoints New CEO to Enhance Shareholder Value
- Leadership Change: Aurinia has appointed Kevin Tang as the new CEO, replacing Peter Greenleaf, a move seen as a positive response to long-standing shareholder demands and a significant shift in corporate governance.
- Compensation Structure Reform: New CEO Tang's decision to accept zero compensation starkly contrasts with former CEO Greenleaf's approximately $26 million payout from 2019 to 2022, which is expected to enhance shareholder confidence and improve financial discipline within the company.
- Cost-Saving Measures: The new management has reduced the board size from nine to six members and discontinued non-core R&D programs generating over $50 million annually, which is anticipated to save substantial costs and further enhance capital allocation efficiency.
- Share Repurchase Program Launch: Aurinia has initiated a $150 million stock repurchase program aimed at increasing earnings per share by reducing the number of shares outstanding, reflecting the company's commitment to shareholder value creation.
See More
